Quantitative gDNA TCR/BCR Sequencing with RepSeq IQ™
To fully understand the immune response to disease and advance therapeutic development, it is crucial to sequence the Adaptive Immune Receptor Repertoire (AIRR) and quantify adaptive immune cell gene expression. However, using whole transcriptome RNA-seq to characterize the expression of key immune gene markers results in complicated bioinformatics analysis and decreased sensitivity.
At iRepertoire, we have developed ImmunoSight, a fully customizable, targeted NGS assay that quantifies the expression of 150+ immunophenotype genes alongside AIRR sequence data, at bulk or single-cell resolution, to provide biopharmaceutical researchers with the comprehensive data needed to move forward their clinical development and drug discovery programs.
Analyze immunophenotype-specific genes as part of your manufacturing release criteria.
Extract reliable TME gene expression data from clinical samples, including FFPE-derived RNA, to assess the impact of TME markers on immunotherapy efficacy.
Measure patient immune response during clinical trials and reveal biomarkers indicative of therapeutic safety and efficacy.
ImmunoSight leverages oligo-dT reverse RNA transcription using UMI-enabled dam-PCR chemistry and gene-specific primers for 150+ genes carefully selected to characterize a wide range of immune phenotypes along with the AIRR.